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CLINICAL TRIAL STUDY
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Abstract:
Background:
Sustained Acoustic Medicine (SAM) is an emerging, non-invasive, non-narcotic, home-use ultrasound therapy for the daily treatment of joint pain.
The aim of this multi-site clinical study was to examine the efficacy of long-duration continuous ultrasound combined with a 1% diclofenac
ultrasound gel patch in treating pain and improving function in patients with knee osteoarthritis.
Methods:
The Consolidated Standards of Reporting Trials (CONSORT) were followed. Thirty-two (32) patients (18-males, 14-females) 54 years of average
age with moderate to severe knee pain and radiographically confirmed knee osteoarthritis (Kellgren-Lawrence (KL) grade II/III) were enrolled for
treatment with the SAM device and diclofenac patch applied daily to the treated knee. SAM ultrasound (3 MHz, 0.132 W/cm2, 1.3 W) and 6 grams
of 1% diclofenac were applied with a wearable device for 4 hours daily for 1 week, delivering 18,720 Joules of ultrasound energy per treatment.
The primary outcome was the daily change in pain intensity using a numeric rating scale (NRS 0-10), which was assessed prior to intervention
(baseline, day 1), before and after each daily treatment, and after 1 week of daily treatment (day 7). Rapid responders were classified as those
patients exhibiting greater than a 1-point reduction in pain following the first treatment. Change in Western Ontario McMaster Osteoarthritis
Questionnaire (WOMAC) score from baseline to day 7 was the secondary functional outcome measure. Additionally, a series of daily usability and
user experience questions related to devising ease of use, functionality, safety, and effectiveness, were collected. Data were analyzed using t-tests
and repeated measure ANOVAs.
Results:
The study had a 94% retention rate, and there were no adverse events or study-related complaints across 224 unique treatment sessions. Rapid
responders included 75% of the study population. Patients exhibited a significant mean NRS pain reduction over the 7-day study of 2.06-points
(50%) for all subjects (n=32, p<0.001) and 2.96-points (70%) for rapid responders (n=24, p<0.001). The WOMAC functional score significantly
improved by 351 points for all subjects (n=32, p<0.001), and 510 points for rapid responders (n=24, p<0.001). Over 95% of patients found the
device safe, effective and easy to use, and would continue treatment for their knee OA symptoms.
Conclusion:
Sustained Acoustic Medicine combined with 1% topical diclofenac rapidly reduced pain and improved function in patients with moderate to severe
osteoarthritis-related knee pain. The clinical findings suggest that this treatment approach may be used as a conservative, non-invasive treatment
option for patients with knee osteoarthritis. Additional research is warranted on non-weight bearing joints of the musculoskeletal system as well as
different topical drugs that could benefit from improved localized delivery.
Clinical Trial Registry Number: (NCT04391842).
Keywords: Sustained acoustic medicine, Sonophoresis, Diclofenac, Anti-steroidal anti-inflammatory drugs, Long-duration continuous ultrasound,
Low-intensity continuous ultrasound, Pain management.
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1. INTRODUCTION
Osteoarthritis (OA) affects 37.4% of adults in the United
States over the age of 60, costing the American economy
approximately $60 billion per year [1]. OA development is
related to genetic factors, aging, obesity, and joint
misalignment [2 - 5]. Progression of OA is associated with
chronic pain, joint instability, stiffness, narrowing, and joint
degeneration [3 - 7]. While the underlying mechanism of OA
progression and associated pain is not well understood,
inflammation plays an important role in the degradation of
affected joints over time. Treatment of OA is limited to pain
management, reducing joint stiffness, improving range of
motion, function, and the patient's quality of life living with the
disease [8]. Current symptomatic treatment of OA includes
weight loss, exercise, physical therapy, acupuncture,
therapeutic ultrasound, hyaluronic acid injection, systemic or
topical application of nonsteroidal anti-inflammatory drugs
(NSAIDs), and surgical intervention. Many of these treatments
provide transient pain relief, break the integrity of the skin, and
have long term adverse side effects or procedural risk [8 - 15].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of
the most common treatments of OA and have been used to
manage OA associated pain for decades. Long-term use of
systemic NSAIDs have adverse effects on the kidney, liver,
and gastrointestinal system [9, 16 - 18], while the topical
application of NSAIDs has limited penetration through the skin
[9, 19]. Recently, multiple meta-analyses have shown higher
efficacy of diclofenac relative to other NSAIDs such as
ibuprofen, celecoxib, and ketoprofen [20, 21]. Multiple studies
have used different methods to increase the efficacy of
diclofenac penetration through the skin, such as using skin
penetration enhancers, electroporation, iontophoresis, and
sonophoresis [22 - 25].
Ultrasound has been considered a potential therapy to
alleviate pain associated with OA progression [26 - 29]. The
effectiveness of ultrasound therapy is highly dependent on
multiple parameters such as intensity, duty cycle, frequency,
duration of application, and energy dose [30, 31]. Sustained
Acoustic Medicine (SAM) has emerged in the last decade as a
well-controlled, high-dose, home-use ultrasound treatment for
patients with musculoskeletal injuries [32 - 35]. Multiple metaanalyses have shown that ultrasound with correct dosing can be
used as stand-alone or adjunctive therapy to manage OA
associated pain [29, 36 - 38]. Huang et al. (2005) showed the
effectiveness of ultrasound (25% duty, 1 MHz, 2.5 W/cm2) as
adjunct OA therapy improving physical activity. Patients
showed an increase in knee range of motion (ROM) and a
decrease in pain on the visual analog scale (VAS) after 8 weeks
of treatment [27].
Similarly, Yang et al. (2006) reported a significant increase
in VAS scores after 28 days for ultrasound treatment for OA
[39]. In two series (n=12, n=7) of SAM wearable, longduration, continuous ultrasound studies on knee OA, Langer et
al. (2014) reported that daily SAM treatment for 12 to 60 days
significantly reduced pain by 52% (2 to 4 -points improvement
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on the VAS), and demonstrated a 20% improvement in joint
function for the active versus placebo treatment group. The
authors concluded that the SAM studies were underpowered
for the determination of clinical significance and that a larger
clinical trial was warranted [40]. Langer et al. (2015) reported
in a 47 patient, randomized placebo-controlled study (28 active
and 19 placebo) on SAM treatment of radiographic mild to
moderate clinical knee OA (Grade 1–2 on the Osteoarthritis
Research Society International (OARSI) scale), and
demonstrated that patients with moderate to severe pain had a
2.5-point reduction in pain on the VAS over 42 days of
treatment which was statistically significant over the placebo
1.23-point decrease. The authors concluded that reduction in
OA pain was clinically meaningful and exceeded The Initiative
on Methods, Measurements, and Pain Assessment in Clinical
Trials (IMMPACT) guidelines [34]. In a double-blind,
randomized, placebo-controlled clinical trial on SAM treatment
for knee OA by Draper et al. (2018), 93 patients with moderate
to severe pain and mild radiographic knee OA (KellgrenLawrence grade I/II) had a significant 1.96-point pain
reduction for active versus 0.85 point reduction for placebo on
a numeric rating scale (NRS). Patients receiving active SAM
treatment also had significant improvement in pain, stiffness,
and function on the Western Ontario and McMaster
Universities (WOMAC) scale compared with placebo (500 vs.
311, respectively). The authors concluded that SAM treatment
significantly reduced pain and improved joint function in
patients with moderate to severe OA knee pain and could be
used as a conservative treatment option for patients with knee
OA [33]. A recent 2019 systematic review and meta-analysis
on ultrasound dosing for knee OA demonstrated that regular
ultrasound treatment significantly relieved pain and reduced
the WOMAC physical function score. Ultrasound also
increased the active range of motion and reduced the Lequesne
index. The authors concluded that regular ultrasound treatment
is safe and effective at relieving pain and improving physical
function in patients with knee OA [37, 41]. The objective of
this study was to determine the efficacy of long-duration
continuous ultrasound delivered by the SAM device combined
with 1% diclofenac for the symptomatic treatment of knee OA
pain. We hypothesized that combining SAM with topical
diclofenac would provide more rapid pain reduction for
patients compared with prior SAM studies reported in the
clinical literature.
2. METHODS
The study and methods followed the Consolidated
Standards of Reporting Trials (CONSORT) [42]. The
prospective multi-site study was conducted in the Central New
York and Southern Coastal Connecticut regions of the United
States between June 2019 and January 2020 registered with
ClinicalTrials.gov identifier NCT04391842. Patient enrollment
was accomplished through referrals from Cayuga Medical
Center and the Yale-New Haven Health System community
hospitals, to Medical Pain Consultants and Sport and
Orthopaedic Physical Therapy, affiliated outpatient care
practices, respectively. The practices served as the setting for
enrollment, training on the use of the device, visits of the
patients with research staff, and pre/post functional
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measurements. The patient's home/work setting served as the
setting at which the device was self-administered and where
pain measurements were recorded. The study was approved by
the institutional review board of the Integ Review, and all
patients provided informed consent to participate. The
procedures followed were in accordance with the ethical
standards of the responsible committee on human
experimentation and with the Helsinki Declaration of 1975, as
revised in 2000 [43].
Included patients were 45 to 85 years of age, reported
moderate to severe knee OA pain negatively affecting their life,
were radiologically confirmed to have mild to moderate OA
(Kellgren-Lawrence (KL) grade II-III score) in one or both
knees, had baseline day-1 pain Numerical Rate Score (NRS
0-10) pain between 3 and 7, had no intraarticular injection to
the treated knee in the last 6 months, had no trauma to the
treated knee, and had no implants or surgeries to the treated
knee. In cases of bilateral knee OA, the more painful knee was
selected for treatment; if equal pain, a flip of a coin was used to
select the knee for treatment. Participants were excluded if they
had KL score greater than III, showed an inability to apply the
device, were currently using a steroid-based medication, had a
recent history of trauma to the knee or having osteoarthritis
develop secondary to a metabolic disorder.
Patients meeting inclusion criteria were enrolled for a 7day treatment with SAM ultrasound device and 1% diclofenac
ultrasound coupling patch. Patients subsequently self-applied
the respective treatment 4 hours per day for 1 week to the
lateral and medial arthritic knee, as shown in Fig. (1).
Measurements of pain before and after daily application of
SAM and ease of use were recorded in a daily patient diary,
while functional measurements were completed during clinic
visits.

Madzia et al.

The clinical sample size for the study was determined from
Draper et al. (2018) using the mean knee OA pain reduction
from SAM treatment for the first 2 weeks of the study (active
mean 3.61 ± 2.53) and mean baseline pain of the study group
(mean 5.53 ± 2.37); A sample size of 23 patients provided over
95% power for the primary outcome measure NRS pain
reduction. We conservatively targeted enrollment of 30 patients
anticipating insignificant (less than 5%) dropouts for the 1week study. We also anticipated a stronger treatment effect size
for pain reduction in our study since SAM was to be applied
for 4-hours with topical diclofenac per treatment versus only
SAM in Draper et al. (2018). Total participants completing the
study was slightly above target (+2).
2.1. Baseline Measurements and Intervention Protocol
The patients' initial NRS and Western Ontario and
McMaster Universities Arthritis Index (WOMAC) scores were
recorded at the outpatient care facilities on Day 1 of the study.
Patients were trained to use the Sustained Acoustic Medicine
(SAM) device along with diclofenac patch and record NRS
pain scores before the treatment and post 4-hour treatment in
daily diaries for 7 days. SAM® Pro 2.0 (ZetrOZ Systems LLC,
Trumbull, CT) is a portable, wearable, US Food and Drug
Administration FDA-approved Class II medical device for
prescription home-use ultrasound treatment. The SAM device
delivers ultrasound at 3 MHz, 100% duty cycle, 1.3 W with
132 mw/cm2 intensity per transducer and overall energy
delivery of 18,720 Joules over 4 hours of treatment. The device
is attached to the body with a disposable adhesive patch which
was pre-filled with 3g ultrasonic coupling gel with 1%
diclofenac provided by the manufacturer (Fig. 1).

Fig. (1). Sustained Acoustic Medicine (SAM) ultrasound device applied to the medial and lateral articulation points of the knee with 1% diclofenac
ultrasound coupling patch.
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At the clinics, patients were shown how to apply the
disposable adhesive patches/transducers to the medial and
lateral sides of the arthritic knee and set the medical devices
treatment timer for 4 hours of continuous ultrasound (Fig. 1).
Patients were instructed to wear the device during regular daily
activity and apply/remove the device when convenient with
their daily schedule. Each patient received one rechargeable
device and 18 disposable, single use, diclofenac ultrasound gel
adhesive patches. Patients were instructed to apply the device
daily and record pain and usability questions daily in the diary.
Patients recorded the primary outcome NRS (0 – 10, 0 = no
pain, 10 = extreme pain) at pre-treatment and post-treatment
over 7 days. The secondary outcome WOMAC was recorded at
the outpatient care practices at the beginning of the study and
after 7 days of treatment, evaluating activity, stiffness, and
function of the treated knee.
2.2. Follow-up and Statistical Analysis
Once enrolled in the study, patients completed outpatient
care facility visits on day 1 (patient screening, enrollment and
informed consent) and day 7 (study completion). During the
week, the research staff talked with the patient once on the
phone to review the daily pain diary, addressed any questions
the patient had about using the device or being involved in the
study, and monitored for any adverse events (i.e., a serious
unanticipated injury or death) or reactions (e.g., skin
sensitivity, redness or burn) from the device.
Change in NRS pain score from baseline was analyzed for
pre and post-treatment each treatment day throughout the
study, and WOMAC (pain, stiffness, and functional change)
was evaluated on day 1 and day 7. Demographic and outcomes
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data were analyzed using t-tests and repeated measure
ANOVAs. Based on the primary outcome measure, rapid
responders were considered to have greater than a 1-point
reduction in pain on the first treatment. Chi-squared
proportional assessment was used to assess gender
demographics between groups. Data analysis was conducted in
the R software environment for statistical computing (The R
Foundation for Statistical Computing, Vienna, Austria). Data
are expressed as means ± SDs (standard deviations). The pvalues of less than 0.05 were considered statistically
significant.
3. RESULTS
A total of 38 patients were screened. Thirty-four [33]
patients were eligible and enrolled in the study. Thirty-two [31]
completed the study. The two dropouts were non-study related
on the first day of the protocol (one due to family and one due
to influenza), resulting in a 94% retention rate. A total of 18
males and 14 females completed the 7-day study (Fig. 2). The
patient demographics for treatment intervention include
subjects with mean age 53.6 ± 8.5 years and body mass index
(BMI) 32.8 ± 8.8. Patients reported moderate knee OA pain at
baseline, average NRS 4.06± 2.39. No significant differences
or trends were found between baseline pain and BMI by
gender. Approximately 62% (20 patients) of the study
population were non-Hispanic Caucasian and 38% (12
patients) non-Hispanic African American. Enrolled patients
were currently seeing medical care for knee osteoarthritis pain.
The most common pain medications were prescription NSAIDs
and oxycodone. The most common non-drug pain treatment
was physical therapy and light exercise. Cointervention results
were not investigated in this study.

Participant Screened N= 38
Participant Included - All
- 45 – 85 years of age
- Mild to moderate OA (KL II/III)
- NRS Score ≥ 3
Participant Included – Rapid Responders
- 1-point drop in NRS on 1 day

Participant Excluded
- Intraarticular injections
- Surgeries in past six months
- Use of opioid-based medication
- Implants or trauma
Day 1 – Participants’ WOMAC
recorded

Participant Enrolled (n=34)

Drop out - 2
(1-family issues, 1 influenza

Day 1 – 7 Pre-Treatment
and Post-Treatment NRS
Score recorded

All Participants (n=32)
Day 7 – Participants’ WOMAC
recorded
Rapid Responders (n=24)
>1 point NRS change Day 1

Fig. (2). Flow chart illustrating study design: Participants screening, exclusion criteria, and data collection time points.
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Fig. (3). Numeric Rating Score: A) “All Subjects n=32” NRS pain showing significant decrease in pain from day 1 through day 7 of treatment. Pain
was reduced by 50% from start to end of study (2.06 NRS, p<0.001). B) “Rapid Responder n=24” NRS showing significant decrease over 7 days of
study. Pain was reduced by 70% from start to end of study (2.96 NRS, p<0.001).

3.1. Primary Outcome Measure of Knee OA Reduction in
Pain on NRS Scale

decreased daily from baseline day 1 to day 2 to day 3…day 7
(Fig. 3).

Knee osteoarthritis pain was significantly reduced daily
and over the course of the 7-day treatment regimen for both the
entire study cohort (100%, n=32) and rapid responders (75%,
n=24). For the entire patient cohort, the pretreatment day 1
baseline pain was 4.06 ± 2.39, and after 7 days of treatment,
pain decreased to 2.00 ± 2.41, 2.06-point change 7 days (50%
decrease, p<0.001, Fig. 3A). The application of SAM with
diclofenac patch provided the largest significant daily decrease
in pain on the first two days of the study with continued pain
reduction thereafter (Fig. 3).

3.2. Secondary Outcome of Knee Functional Improvement
on WOMAC Scale

Rapid responders showed a more significant reduction in
the NRS pain score. Day 1 baseline pain of 4.26 ± 2.41 to
1.30± 1.5, 2.96-point decrease (70% decrease, p<0.001) over 7
days of treatment (Fig. 3B). Pain reduction significantly

The WOMAC score measuring the change in pain,
stiffness, and functionality of the knee was significantly
improved for SAM with diclofenac patch by 351 points for all
subjects (n=32, p<0.001, Fig. 4A), and 510 points for rapid
responders (n=24, p<0.001, Fig. 4B). For all subjects, pain
score improved by 66-points (p<0.0001), stiffness score
improved by 41 points(p<0.001), and functionality score
improved by 244 points (p< 0.001) (Table 1). For rapid
responders, pain score improved by 92 points (p<0.0001),
stiffness score improved by 55 points (p<0.0001), and
functionality score improved by 364 points (p<0.0001) (Table
2).

Table 1. WOMAC table for all subjects n=32: Shows the baseline score and score after 7 days of treatment. SAM with
diclofenac significantly reduced pain and stiffness and improved functionality.
-

Pre-Treatment

Post-Treatment

Mean 95% CI

p value

WOMAC Pain

240 ± 110

173 ± 146

-101 to -32

0.0005

WOMAC Stiffness

125 ± 42

84 ± 61

-61 to -22

0.0002

WOMAC Functionality

803 ± 393

559 ± 481

-356 to -132

0.0001

WOMAC Total

1168 ± 528

816 ± 678

-508 to -195

< 0.0001

Table 2. WOMAC table for rapid responders n=24: Shows better response to SAM with diclofenac treatment than “All
Subjects” with significant decreases in pain and stiffness, and improved functionality over 7 days of treatment.
-

Pre-Treatment

Post-Treatment

Mean 95% CI

WOMAC Pain

235.42 ± 108.33

143.75 ± 140.73

-132.9 to -50.41

p Value
0.0005

WOMAC Stiffness

124.96 ± 40.38

69.79 ± 60.37

-81.76 to -28.57

< 0.0001

WOMAC Functionality

800.22 ± 393.48

436.46 ± 445.05

-557.3 to -170.2

< 0.0001

WOMAC Total

1160.59 ± 480.81

650 ± 635.62

-745.2 to -276.0

< 0.0001
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Fig. (4). WOMAC Functional Score: A) Significant 351-point (p<0.001) decrease in WOMAC score after 7 days of SAM with diclofenac treatment
in all subjects n=32. B) Rapid Responders n=24 shows more robust 510-point (p<0.001) WOMAC decrease in response to the SAM with diclofenac
treatment over 7 days.

3.3. Secondary Outcome of Treatment Usability and
Satisfaction
There were no adverse events or study-related complaints
across 224 unique treatment sessions. There were no reports of
skin burn, skin irritation, or skin sensitization. Over 95% of
patients found the device safe, effective, and relatively easy to
use and would continue treatment for their knee OA symptoms.
By day 7 of the study, 100% of patients in the study reported
the device was very easy to use and apply.
4. DISCUSSION
Osteoarthritis (OA) is a progressive disease of the joints,
resulting in the degradation of cartilage and bone, leading to a
reduction of joint space and increased inflammatory response
over time [3, 7, 44]. NSAIDs, along with physical therapy,
have shown limited efficacy in managing OA associated pain
[9, 14, 19, 26, 44, 45]. For many patients, the risks associated
with the long-term systemic use of NSAIDs outweigh the
modest benefit. While a localized, topical application of
NSAIDs is safer for knee OA pain, the efficacy is limited due
to drug delivery rates through and across the skin [9, 46].
Diclofenac is one of the more effective and prescribed NSAIDs
for OA associated pain [20, 21, 38, 47, 48]. This study used a
wearable multi-hour sustained acoustic medicine (SAM) device
with 1% diclofenac patch to treat OA associated pain and
improve mobility and overall quality of life of patients. SAM
applies continuous long-duration ultrasound along with
localized delivery of diclofenac to decrease patients' knee OA
pain and improve joint function. In prior preclinical research,
SAM has demonstrated the 3.8x increase of diclofenac
penetration into and across the skin [49], along with drug
delivery enhancement of other drugs over 4-hour treatment
protocols [49, 50].

The wearable SAM device and 1% diclofenac ultrasound
gel patch could be successfully self-applied by patients for use
in the home, providing significant pain relief of KL grade II/III
knee OA. No adverse events were noted in the study
population, and 94% of participants completed the study.
Participants in the study had between a 50% (2.06-point) to a
(70%, 2.96-point) pain reduction on the NRS scale. The NRS
pain data show an incremental decrease in pain throughout the
7-day treatment with the highest rate of reduction in pain
during the first two days. This outcome may be explained by
increased penetration of diclofenac into the joint space leading
to inhibition of COX1 and COX2 pathways [20, 38], thus
relieving the inflammatory response in the joint. Masterson et
al. (2020) demonstrated SAM increased transdermal diclofenac
delivery 3.8 fold greater than topical application alone [51],
which were similar to the results of transdermal salicylic acid
delivery with SAM by Langer et al. (2013) [49]. The sustained
treatment and continued pain reduction over the 7-days suggest
the potential of lower levels of cytokines to retain pain at a
decreased intensity. Functionally, the WOMAC score
improved significantly for patients with KL grade II/III knee
OA by 351 points for all subjects (n=32, p<0.001) and 510
points for rapid responders (n=24, p<0.001). The improvement
in the WOMAC score is indicative of the overall improvement
of function and quality of life.
Ultrasound has been shown to be an effective pain
management method for arthritis-associated knee pain [29, 37,
45, 52 - 56]. Draper et al. (2018) demonstrated a 1.96-point
pain reduction on NRS and improvement in total WOMAC
score by 505 points comparing the application of SAM active
continuous long-duration ultrasound to the placebo group in a
93-subject double-blind, randomized controlled study [33].
This resulted in a 40% knee OA pain reduction for the active
treatment group and a 16% pain reduction for the placebo
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group over 6 weeks of daily treatment. In the current study, we
found a 50-70% pain reduction in 1 week of daily SAM with
diclofenac patch treatment (Fig. 5). Similarly, Langer et al.
(2014, 2015) reported a 40% and 48% reduction in knee OA
pain after 6 weeks of daily SAM treatment in two pilot case
series and one placebo-controlled study, including 66 subjects
in total. The current study did not include a placebo group but
had similar inclusion criteria, baseline pain, the severity of
knee OA (KL grade II/III), and patient demographics.
Therefore, the more rapid and robust pain reduction can be
attributed to the addition of the 1% diclofenac ultrasound gel
coupling patch. Yang et al. (2006) has also reported on the
efficacy of ultrasound in the reduction of pain with a
combination of NSAIDs [39].
Sustained therapeutic ultrasound has also been shown to
contribute to improved cartilage thickness. Özgönenel et al.
(2018) has reported that the application of continuous
therapeutic ultrasound in 30 patients showed a significant
reduction in visual analog scale (VAS) and WOMAC scores,
and improved cartilage thickness in medial femoral condyle
after 10 sessions of treatment in a double-blinded trial [31].
Loyola-Sánchez et al. (2012) also reported encouraging effects
of ultrasound application in managing mild to moderate knee
OA in a double-blinded randomized study in 27 patients with a
significant increase in cartilage thickness after 20 sessions [57].
Additionally, recent studies and meta-analysis show the
efficacy of ultrasound on knee OA pain. Still, the clinical
outcome significantly depends on ultrasound parameters such
as 1-3MHz frequency, duty cycle, duration, and total energy
delivered over treatment time [29, 45, 55].
The FDA approved non-invasive prescription home-use
SAM device has little to no adverse effects reported and the
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contraindications are similar to traditional therapeutic
ultrasound [33 - 35, 40, 58]. The SAM device with a diclofenac
patch delivers 18,720 Joules of ultrasonic energy and 6g of 1%
diclofenac ultrasound gel daily to the arthritic knee of patients.
The continuous long-duration ultrasound treatment and locally
delivered diclofenac reduce patient pain and improve joint
function without requiring systemic NSAID use. The
application of SAM to the joint also has diathermic effects [35,
59], which increase the blood flow, oxygenation, and exchange
of nutrients. The SAM diclofenac patch ensures ease of patient
application of localized diclofenac delivery and a decrease of
cytokines such as cyclooxygenase 1 and 2, interleukine 1 β,
TNF α, and relative pathways [19, 44, 60 - 65]. The
mechanotransductive force of long duration ultrasound along
with increased permeability and transport kinetics across the
skin leads to increased drug penetration through the skin as
well as increased blood flow, which increases the drug
penetration into the affected tissue [39, 41, 66 - 69].
Recent preclinical and clinical studies have shown that
ultrasound therapy has chondroprotective effects by inhibiting
inflammatory factors [36, 52, 64, 70 - 72]. The combined
enhanced drug delivery of diclofenac and ultrasound
chondroprotective effect makes SAM combined with
diclofenac an effective treatment for arthritis associated pain.
The current study shows the efficacy of SAM with a 1%
diclofenac ultrasound coupling patch in OA patients in a homeuse environment, with a significant clinically meaningful
decrease in pain and joint stiffness and an increase in
functionality and overall quality of life. While the current study
did not evaluate the effect of SAM on cartilage, given the short
duration of the study, future research is needed to determine
the role of sustained, continuous ultrasound as an OA diseasemodifying agent.

Fig. (5). Pain reduction of current study compared with Draper et al. (2018). One week of daily SAM with diclofenac patch treatment provides an
additional 10% to 30% pain reduction for patients 5 weeks faster than prior reported literature for long-duration ultrasound treatment.

Sustained Acoustic Medicine Combined with A Diclofenac Ultrasound Coupling Patch

The SAM device is one of two prescription home-use (1 to
3MHz) ultrasound devices available in the USA. The other
device (Exogen®, Bioventus LLC, Durham, NC) was approved
by the FDA in the early 1990s for non-thermal application and
used a pulsed 20-minute daily ultrasound treatment at a low
energy level (140 Joules per 20-minute treatment) [73, 74]. The
SAM energy level is approximately 133 times greater and
therefore generates significant thermal and non-thermal effects
on tissue. The SAM devices used in this study cost $6800,
which is significantly less costly than surgery or comorbidities
developed from systemic drug use for chronic diseases. SAM
treatment should be considered for patients with moderate knee
OA pain as a cost conservative treatment option. Future
research on long-duration ultrasound as a means for localized
drug delivery of NSAID and reduced osteoarthritis disease
progression is of great interest. Additional studies could
evaluate the dosimetry of SAM and NSAID to provide
clinically meaningful pain reduction further while minimizing
the use of drugs. The use of SAM with other topical agents
such as dexamethasone before, during, and after SAM
treatment may also be of interest to the clinical community
[75].
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